Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice.
Ontology highlight
ABSTRACT: Sickle cell disease (SCD) is caused by a monogenic mutation of the β-globin gene and affects millions of people worldwide. SCD is associated with sustained hemolytic anemia, vasoocclusion, ischemia-reperfusion injury, oxidative tissue damage, inflammatory cell activation, and systemic endothelial dysfunction. The transcription factor Nrf2 coordinates the expression of a wide variety of genes encoding antioxidant, detoxification, and metabolic enzymes. Nrf2 participates in suppressing proinflammatory cytokines and organ protection in SCD. However, little is known regarding the mechanisms by which Nrf2 ameliorates SCD pathology or how some cells respond to Nrf2 stimuli to alleviate SCD pathology. Here, we asked whether monocytes/granulocytes and/or endothelial cells are particularly critical
SUBMITTER: Keleku-Lukwete N
PROVIDER: S-EPMC6482351 | biostudies-literature | 2019 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA